Target intelligence / Profile preview

Torsin family 1 member B (TOR1B)

Target
TOR1B
Molecular classification
AAA+ ATPase enzyme (ATPases Associated with diverse cellular Activities), Protein chaperone (functionally implicated), Molecular machine involved in protein folding and membrane integrity
01

Overview

TOR1B encodes a member of the **AAA+ ATPase family**, a group of ATP-hydrolyzing enzymes essential for diverse cellular processes. The protein localizes mainly to the nuclear envelope and endoplasmic reticulum, where it acts as a chaperone to maintain membrane integrity and support protein folding. It shares high similarity and possible functional redundancy with its paralog, TOR1A, and is notably expressed in neural tissues, suggesting roles in synaptic function and neuronal development. Recent research implicates **TOR1B in cancer biology**, especially in aggressive breast cancer subtypes, where its overexpression is associated with poor prognosis and metastatic potential. It also has a genetic link to idiopathic dystonia in tandem with TOR1A. While no targeted drugs are approved for TOR1B, its function as a chaperone and mediator of cellular stress responses makes it a candidate for future therapeutic intervention and a promising biomarker in oncology[1][3][4][5].

Other names
Torsin-1BDQ1FKSG18MGC4386Torsin ATPase-1BTorsin B
02

Mechanism of action

Not established—targeted modulation could impact ATPase activity, protein folding, and cellular stress responses

03

Biological functions

ATP hydrolysis (utilizes ATP for energy)Molecular chaperone (protein folding assistance)Maintenance of nuclear envelope and endoplasmic reticulum integrityRegulation of cellular homeostasisPossible role in synaptic functioning and neural developmentInvolvement in apoptosis and adaptation to cellular stress in cancer cells
04

Disease associations

Cancer (notably basal-like breast cancer; prognostic biomarker for bone metastasis in receptor-positive breast cancers)Neurodegenerative disease (implicated in idiopathic dystonia along with TOR1A)Other reported associations: Acute Endophthalmitis, Lobomycosis
05

Safety considerations

No direct safety issues reported for targeting TOR1B; challenges would be typical for targeting essential cellular maintenance proteins, particularly in non-cancer tissues
06

Interacting drugs

No drugs specifically targeting TOR1B currently listed in available sources

1 more in the full profile.

07

Biomarkers

TOR1B expression level: emerging biomarker for predicting bone metastasis in breast cancer patientsHigh TOR1B levels correlate with poor prognosis in certain cancers

Beyond the preview

Go deeper on Torsin family 1 member B (TOR1B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Torsin family 1 member B (TOR1B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call